Jyong Biotech Ltd. has reaffirmed its strategy of pursuing global licensing partnerships as it advances the development of Botreso (API-1), an investigational botanical drug candidate for benign prostatic hyperplasia (BPH). The announcement reflects the company's broader effort to commercialize plant-derived therapeutics internationally while addressing a growing medical need driven by aging populations worldwide.

The Nasdaq-listed biotechnology company said it is continuing discussions with pharmaceutical companies and industry partners following its participation at the BIO 2026 International Convention. Rather than focusing solely on direct commercialization, Jyong Biotech is positioning licensing agreements and strategic collaborations as a key route to expanding its international footprint.

The strategy comes as the global market for BPH treatments continues to grow. Benign prostatic hyperplasia, a non-cancerous enlargement of the prostate gland, is one of the most common urological conditions affecting older men. The disease can significantly impair quality of life by causing urinary symptoms such as frequent urination, urgency, weak urine flow, incomplete bladder emptying, and nighttime urination. If left untreated, severe cases may contribute to urinary tract infections, bladder stones, urinary retention, and kidney complications.

According to research cited by the company from the Global Burden of Disease (GBD) 2021 study and BMC Urology, approximately 112.5 million people were living with BPH globally in 2021, more than double the estimated patient population recorded in 1990. The number of patients is projected to reach between 150 million and 156 million by 2035, highlighting the long-term healthcare challenges associated with population aging.

That patient growth is expected to drive continued expansion of the BPH treatment market. Industry estimates referenced by Jyong Biotech project the global market will increase from approximately $13 billion in 2025 to between $22 billion and $22.6 billion by 2035, representing nearly 70% growth over the decade.

Despite the expanding commercial opportunity, the company argues that significant unmet clinical needs remain. Existing BPH therapies primarily rely on alpha-blockers and 5-alpha reductase inhibitors (5-ARIs), treatments that can effectively relieve symptoms but are frequently associated with side effects including dizziness, low blood pressure, ejaculatory disorders, and sexual dysfunction. High discontinuation rates continue to present a challenge for physicians seeking long-term disease management solutions.

Jyong Biotech is attempting to differentiate itself through a botanical drug development platform focused on plant-derived therapeutics. Unlike traditional herbal supplements, botanical drugs undergo standardized pharmaceutical development and regulatory evaluation, including clinical trials designed to demonstrate safety, quality, and efficacy.

The company noted that Botreso has completed four Phase III clinical trials conducted across Taiwan and the United States, involving research contributions from more than 200 urologists. While these studies represent a significant milestone for the development program, the company emphasized that Botreso remains an investigational drug candidate and has not received regulatory approval for commercial use in any market.

Jyong Biotech also highlighted its position as the first company from Taiwan to advance an oral botanical drug into Phase III clinical trials under the U.S. Food and Drug Administration's regulatory pathway. That milestone underscores growing interest in evidence-based botanical medicines as pharmaceutical developers explore alternative therapeutic approaches for chronic diseases.

The company's commercialization strategy aligns with broader trends reshaping the biotechnology sector. Increasingly, emerging biotech firms are pursuing licensing partnerships with larger pharmaceutical companies to accelerate clinical development, regulatory approvals, manufacturing scale-up, and global market access. Such collaborations allow smaller innovators to leverage established commercial infrastructure while reducing financial risk associated with bringing new therapies to market.

The announcement follows Jyong Biotech's recent participation in BIO 2026, one of the biotechnology industry's largest partnering events, where companies typically seek licensing, investment, and research collaborations. Continued discussions with global pharmaceutical companies suggest Jyong Biotech is positioning Botreso as a potential licensing asset rather than pursuing independent commercialization across multiple regions.

The biotechnology industry is also experiencing rising interest in therapies addressing age-related diseases. According to the United Nations, the global population aged 65 and older is expected to more than double by 2050, creating sustained demand for treatments targeting chronic conditions associated with aging. Meanwhile, Grand View Research projects continued expansion of the global urology therapeutics market as healthcare systems increasingly prioritize treatments that improve long-term patient outcomes and quality of life.

For pharmaceutical companies, licensing innovative therapies in specialized therapeutic areas such as urology has become an important strategy for strengthening product pipelines while managing research and development costs. If clinical development and future regulatory reviews progress successfully, botanical therapies like Botreso could offer an additional treatment option in a market where patient adherence remains a significant challenge.

Although commercialization timelines remain dependent on regulatory review and future partnership agreements, Jyong Biotech's latest update highlights how emerging biotechnology companies are increasingly combining clinical innovation with strategic licensing models to compete in a global pharmaceutical landscape.

Market Landscape

The global urology therapeutics market is expanding as aging populations drive higher incidence rates of chronic urinary disorders, including benign prostatic hyperplasia. Pharmaceutical companies are investing in therapies that improve patient adherence, reduce treatment-related side effects, and deliver long-term symptom management. At the same time, biotechnology firms are increasingly leveraging licensing partnerships to accelerate commercialization while minimizing development costs and expanding international market access.

Strategic Outlook

Jyong Biotech's licensing-focused strategy reflects a growing trend among clinical-stage biotechnology companies seeking global commercialization through pharmaceutical partnerships. If Botreso demonstrates positive regulatory outcomes, the company could strengthen its position within the emerging botanical drug segment while addressing a large and growing market with significant unmet clinical needs.

Top Insights

• Jyong Biotech is prioritizing global licensing partnerships to commercialize its investigational botanical BPH therapy while expanding collaborations with international pharmaceutical companies.
• The global BPH patient population is projected to exceed 150 million by 2035, creating sustained demand for innovative long-term treatment options.
• Botreso has completed four Phase III clinical trials but remains an investigational drug candidate without regulatory approval for commercial use.
• High discontinuation rates associated with existing BPH medications continue to create opportunities for therapies offering improved tolerability and patient adherence.
• Botanical drug development is emerging as a specialized segment within biotechnology, combining plant-derived compounds with pharmaceutical-grade clinical validation.

Get in touch with our MarTech Experts